VF
RARE icon

Virtu Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Virtu Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,861
Closed -$387K – 2134
2025
Q3 		$387K Buy
12,861
+1,044
+9% +$31.3K 0.02% 652
2025
Q2 		$430K Buy
+11,817
New +$426K 0.02% 624
2021
Q1 		– Sell
-14,202
Closed -$1.97M – 1942
2020
Q4 		$1.97M Buy
+14,202
New +$1.68M 0.21% 109
2019
Q4 		$321K Buy
+7,521
New +$310K 0.03% 647
2019
Q2 		– Sell
-6,229
Closed -$432K – 1782
2019
Q1 		$432K Buy
+6,229
New +$356K 0.02% 632
2018
Q4 		– Sell
-19,617
Closed -$1.5M – 1907
2018
Q3 		$1.5M Buy
19,617
+15,922
+431% +$1.3M 0.09% 228
2018
Q2 		$284K Buy
+3,695
New +$239K 0.02% 1197
2018
Q1 		– Sell
-7,372
Closed -$342K – 2473
2017
Q4 		$342K Buy
+7,372
New +$361K 0.02% 1150

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial's RARE Position: Q4 2025 in Review

Virtu Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 12,861 shares — an estimated $387K sold.

Virtu Financial first reported a position in RARE in Q4 2017 and held it in 8 quarters. The position peaked at $1.97M in Q4 2020. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Virtu Financial reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Virtu Financial sold 12,861 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $387K.
  • Virtu Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 8 quarters.
  • Virtu Financial's Ultragenyx Pharmaceutical position peaked at $1.97M in Q4 2020.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.